Colchicine

Active ingredient: Colchicine

In short: Colchicine tablets are indicated in adults and children four years or older for treatment of familial Mediterranean fever (FMF).

Forms & strengthsTablets: 0.6 mg colchicine- Purple colored, capsule shaped, film coated tablets debossed with "C6" on one side and scored on the other side.
LabelA-S Medication Solutions
Label updatedNov 09, 2026

What is Colchicine used for?

Colchicine tablets are indicated in adults and children four years or older for treatment of familial Mediterranean fever (FMF).

Colchicine dosage

The long-term use of colchicine is established for FMF.

The recommended dosage of colchicine tablets depends on the patient’s age, renal function, hepatic function and use of coadministered drugs .

Colchicine tablets are administered orally without regard to meals.

Colchicine tablets are not an analgesic medication and should not be used to treat pain from other causes.

The recommended dosage of colchicine tablets for FMF in adults is 1.2 mg to 2.4 mg daily.

Colchicine tablets should be increased as needed to control disease and as tolerated in increments of 0.3 mg/day to a maximum recommended daily dose. If intolerable side effects develop, the dose should be decreased in increments of 0.3 mg/day. The total daily colchicine tablets dose may be administered in one to two divided doses.

FMF

The recommended dosage of colchicine tablets for FMF in pediatric patients 4 years of age and older is based on age. The following daily doses may be given as a single or divided dose twice daily:

Children 4 to 6 years: 0.3 mg to 1.8 mg daily

Children 6 to 12 years: 0.9 mg to 1.8 mg daily

Adolescents older than 12 years: 1.2 mg to 2.4 mg daily

Concomitant Therapy

Coadministration of colchicine tablets with drugs known to inhibit CYP3A4 and/or P-glycoprotein (P-gp) increases the risk of colchicine-induced toxic effects (Table 1). If patients are taking or have recently completed treatment with drugs listed in Table 1 within the prior 14 days, the dose adjustments are as shown in the table below .

Table 1. Colchicine tablets Dose Adjustment for Coadministration with Interacting Drugs if No Alternative Available*

Strong CYP3A4 Inhibitors†

Drug | Noted or Anticipated Outcome | FMF

Original Intended Dosage | Adjusted Dose

AtazanavirClarithromycin Darunavir/ Ritonavir‡

Indinavir Itraconazole Ketoconazole Lopinavir/ Ritonavir‡

Nefazodone Nelfinavir Ritonavir Saquinavir Telithromycin Tipranavir/Ritonavir‡ | Significant increase in colchicine plasma levels*; fatal colchicine toxicity has been reported with clarithromycin, a strong CYP3A4 inhibitor. Similarly, significant increase in colchicine plasma levels is anticipated with other strong CYP3A4 inhibitors. | Maximum daily dose of 1.2 – 2.4 mg | Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)

Moderate CYP3A4 Inhibitors

FMF

Drug | Noted or Anticipated Outcome | Original Intended Dosage | Adjusted Dose

Amprenavir‡

Aprepitant Diltiazem Erythromycin Fluconazole Fosamprenavir‡

(prodrug of Amprenavir) Grapefruit juice Verapamil | Significant increase in colchicine plasma concentration is anticipated.Neuromuscular toxicity has been reported with diltiazem and verapamil interactions. …

How to take Colchicine — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Dosing Instructions

Patients should be advised to take colchicine tablets as prescribed, even if they are feeling better. Patients should not alter the dose or discontinue treatment without consulting with their doctor. If a dose of colchicine tablets is missed:

For FMF, take the dose as soon as possible and then return to the normal dosing schedule. However, if a dose is skipped the patient should not double the next dose.

Fatal Overdose

Instruct patient that fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine. Colchicine tablets should be kept out of the reach of children.

Blood Dyscrasias

Patients should be informed that bone marrow depression with agranulocytosis, aplastic anemia and thrombocytopenia may occur with colchicine tablets.

Drug and Food Interactions

Patients should be advised that many drugs or other substances may interact with colchicine tablets and some interactions could be fatal. …

Warnings & precautions

Do not take this medicine if: Patients with renal or hepatic impairment should not be given colchicine tablets in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors except fosamprenavir). In these patients, life-threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses.

Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine . Colchicine tablets should be kept out of the reach of children.

Myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia and aplastic anemia have been reported with colchicine used in therapeutic doses.

Colchicine is a P-gp and CYP3A4 substrate. Life-threatening and fatal drug interactions have been reported in patients treated with colchicine given with P-gp and strong CYP3A4 inhibitors. If treatment with a P-gp or strong CYP3A4 inhibitor is required in patients with normal renal and hepatic function, the patient’s dose of colchicine may need to be reduced or interrupted . Use of colchicine in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors except fosamprenavir) is contraindicated in patients with renal or hepatic impairment .

Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk. Concomitant use of atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, gemfibrozil, fenofibrate, fenofibric acid or benzafibrate (themselves associated with myotoxicity) or cyclosporine with colchicine tablets may potentiate the development of myopathy . Once colchicine is stopped, the symptoms generally resolve within one week to several months.

Colchicine side effects

FMF

Gastrointestinal tract adverse effects are the most frequent side effects in patients initiating colchicine tablets, usually presenting within 24 hours, and occurring in up to 20% of patients given therapeutic doses. Typical symptoms include cramping, nausea, diarrhea, abdominal pain and vomiting. These events should be viewed as dose-limiting if severe, as they can herald the onset of more significant toxicity.

Serious toxic manifestations associated with colchicine include myelosuppression, disseminated intravascular coagulation and injury to cells in the renal, hepatic, circulatory and central nervous systems.

These most often occur with excessive accumulation or overdosage .

The following adverse reactions have been identified with colchicine. These have been generally reversible upon temporarily interrupting treatment or lowering the dose of colchicine.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. …

Drug interactions

Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp). Of the cytochrome P450 enzymes tested, CYP3A4 was mainly involved in the metabolism of colchicine. If colchicine tablets is administered with drugs that inhibit P-gp, most of which also inhibit CYP3A4, increased concentrations of colchicine are likely. Fatal drug interactions have been reported. Physicians should ensure that patients are suitable candidates for treatment with colchicine tablets and remain alert for signs and symptoms of toxicities related to increased colchicine exposure as a result of a drug interaction. Signs and symptoms of colchicine tablets toxicity should be evaluated promptly and, if toxicity is suspected, colchicine tablets should be discontinued immediately. Table 4 provides recommendations as a result of other potentially significant drug interactions. Table 1 provides recommendations for strong and moderate CYP3A4 inhibitors and P-gp inhibitors.

Table 4. …

About this medicine

Colchicine is an alkaloid chemically described as (S)N-(5,6,7,9-tetrahydro-1,2,3, 10-tetramethoxy-9-oxobenzo [alpha] heptalen-7-yl) acetamide with a molecular formula of C22H25NO6 and a molecular weight of 399.4. The structural formula of colchicine is given below.

Colchicine occurs as a pale yellow powder that is soluble in water.

Colchicine Tablets, USP 0.6 mg are supplied for oral administration as Purple colored, capsule shaped, film coated tablets debossed with “C6” on one side and scored on other side., containing 0.6 mg of the active ingredient colchicine, USP. Inactive ingredients: FD&C Blue #2, FD&C Red #40, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, titanium dioxide and triacetin. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5c1ceff7-8f00-48cc-8ea4-678106455ff1. Read the full official label on DailyMed.